Introduction
Numerous factors influence contraceptive use, such as accessibility to family planning facilities, social policy, religion, education, costs and age (1) . Perception of possible physical and psychological effects may influence individual choices of contraceptive methods (2) . The most commonly used methods in developed countries are oral contraceptives and condoms, whereas intrauterine contraception is the most commonly used reversible long-acting method globally according to the United Nations 2013 (3) .
In England, user-dependent methods (oral contraceptives, patches and condoms) have been reported to account for approximately two-thirds of current contraceptive use (4). Combined oral contraception (COC) was reported to be the most common method in all age groups. However, the use of long-acting reversible methods of contraception (LARC), defined as the sum of levonorgestrel-releasing intrauterine system (LNG-IUS), copper intrauterine devices (Cu-IUD) and implants has gradually increased (4). Similar patterns have been reported from France (5) . In the USA, approximately four of every five women who have been sexually active report ever having used COC and an increasing use of LARC (6) .
Modern contraceptive methods are effective if used correctly (7, 8) . A study performed among women requesting pregnancy termination showed that one in three did not use any contraception at the time of conception because they believed they could not become pregnant (9) . Another study reported that 21% of unintended pregnancies occurred while using contraceptive pills (10) . Both demographic as well as behavioral factors impact on this risk, most evident in young women who may be less compliant with the use of COC and progestin-only pills as compared with LARC (8) . LARC methods have been increasingly promoted as first line contraceptives, especially in highly fertile young women, due to their high efficacy and acceptability, and because daily or coital adherence are not required (11) . There is thus a need to assess the current uptake of LARC methods, especially in younger women.
From 2009, new epidemiological studies demonstrated a differential risk of venous thrombosis according to type of progestin in COCs (12) . The European Medicines Agency accordingly updated their recommendations on first line combined pills to be those containing levonorgestrel, norgestimate or norethisterone (13) . Prescribers and other health care providers have an important role and impact on the choice of hormonal contraceptive methods. Therefore, it is of interest to assess prescription patterns in the light of the new evidence-based recommendations.
There is a general lack of comparisons of contraceptive use between countries, but it could be of importance to better understand differences in reproductive patterns. Comparisons between the Nordic countries are feasible due to the availability of national databases.
The primary aim of this study was to describe and compare contraceptive availability and use in the Nordic countries and compare usage by age in the three countries, Denmark, Norway and Sweden. A secondary aim was to assess prescribing patterns in relation to the recommendations from the European Medicines Agency (13) . A third aim was to compare infrastructure parameters which may directly influence contraceptive use.
Material and methods
The Nordic countries comprise Denmark, Finland, Iceland, Norway and Sweden. National prescription data on all different hormonal contraceptives and dosages available on the market from 2010 to 2013 were collected from the Danish Prescription Registry, the Finnish Medicines Agency, the Icelandic Medicines Agency, the Norwegian Prescription Database and the Swedish Board of Health and Welfare. Specific references for these data sources are given online as Supporting Information Appendix S1.
Only 
Key Message
Contraceptive use was highest in Denmark and Sweden. The highest use of combined oral contraceptives was seen in Denmark, LNG-IUS use was highest in Finland and all long-acting reversible methods were most common in Sweden. The highest use of combined oral contraceptives recommended by the European Medicines Agency was in Denmark. depot was expressed as defined daily doses per 100 women in relevant age groups. Total rates were calculated as total use per 100 women aged 15-49 years.
We set the mean duration of use of Cu-IUD and the LNG-IUS to be four years. In the same manner we calculated the equivalent mean duration of implant use to be two years, since these duration periods have been reported previously (14) .
Comparisons were made between the use of COC recommended as first line treatment by the European Medicines Agency, which are low-dose combined pills containing levonorgestrel, norethisterone or norgestimate, and other forms of combined hormonal contraceptive products which are those containing etonogestrel, norelgestromin, drospirenone, gestodene, desogestrel, chlormadinone, dienogest or nomegestrol (13) .
Information regarding sold packages of emergency contraceptive pills containing 30 mg ulipristal acetate or 1.5 mg levonorgestrel for the years 2010-2013 was collected and expressed as the number of yearly sold packages per 100 women aged 15-49 years for each country. Condom sales in four of the Nordic countries were collected from the Swedish Association for Sexuality Education and in Iceland from the Icelandic Association for Sexual and Reproductive Health-IPPF. Use of less reliable contraceptive methods such as avoiding fertile days and coitus interruptus was not estimated.
Demographic data for the Nordic countries for the year 2013 was obtained from the site Facts about the Nordic countries and information about sex education, financial assistance, prescribers, etc., was collected from each Nordic country.
In these pure descriptive assessments, no confidence limits were calculated for the country-specific rates, due to both large sample sizes making even small differences highly significant, and to the complete national data from each country, making such calculations redundant.
Data were collected with permission from the respective national bodies for Denmark and Norway. In Finland, Iceland and Sweden no permission was needed, as this information is publicly available from the national bodies in those countries. Patients were not directly involved in the study since only aggregated data at group-level was used. No ethical permission and consent was therefore needed. This procedure is in accordance with the ethical standards of the Nordic countries regarding the use of national registers. For Norway, the board of the Norwegian Prescription Database reviewed the protocol and gave permission to use the data. Studies using anonymous data from nationwide registers are exempted by Norwegian legislation from institutional regulatory board approvals and written informed consent from the patients. Permission was obtained in 
Results

Demographic data
The fertility rate was highest in Iceland and Sweden and lowest in Denmark and Finland (Table 1 ). The average income was higher in Norway than in the other Nordic countries. The percentage of people born abroad was highest in Sweden (15%) and lowest in Finland (5%) ( Table 1) .
Contraceptive use
The use of hormonal contraception was assessed in 5.8 million women of reproductive age in the five countries. There were only minor differences between the Nordic countries in the available types of hormonal contraceptives according to estrogen dose, progestogen type and route of administration (Table 2 ). In all countries there was a slight increase in hormonal contraceptive use from 2010 to 2013 (Figure 1 ). Finland and Denmark had the highest rate of overall hormonal contraceptive use, increasing from 38 to 40%; Iceland has the lowest use (30-31%) (Figure 1 ).
Combined oral contraception was the most commonly used method in all five countries during 2010-2013; COC use was highest in Denmark followed by Iceland, Finland, Norway and Sweden. The second most used method was LNG-IUS, where Finland was the country with the highest use in all four years (14-15%), followed by the other four countries with approximately 10% use. Progestinonly contraception and implants were most frequently used in Sweden (Figure 1) . Figure 2 shows the use and distribution of hormonal methods in Denmark, Norway and Sweden by age in 2013. The proportion of combined hormonal contraceptive users was highest among teenagers and young adults, and decreased successively with increasing age. For all age groups, Denmark had highest use of hormonal methods. The decrease in COC use by age was partly compensated by an increasing use of LNG-IUS, especially after the age of 30 years in all three countries ( Figure 2 ). Sweden had a continuously higher use of progestin-only pills compared with the other countries.
The mean annual sales of condoms for these years was estimated to be 10 million for Denmark, 11 million for Finland, 0.5 million for Iceland, 13 million for Norway and 20 million for Sweden. = Denmark; = Finland; = Iceland; = Norway; = Sweden. MPA = medroxyprogesterone acetate; EE = ethinyl estradiol; E2 = estradiol; Ijn = depot provera; IUS = intrauterine system.
Long-acting reversible contraception
The use of LARC increased successively over time in all countries except Norway. The highest use of LARC in 2013 was in Sweden (20%) and the lowest use (10%) in Iceland (Figure 1) . The percentage use of LNG-IUS and Cu-IUS varied respectively from 15 and 1% in Finland, to 11 and 7% in Sweden (Figure 1 ).
Use of combined products grouped according to current recommendations
A substantial change in the use of combined products recommended by the European Medicines Agency was observed in Denmark between 2010 (13%) and 2013 (50%). In Finland, non-recommended products were used almost exclusively throughout the study period. The share of the recommended products increased in Iceland and in Norway, contrasting with a slight decrease in Sweden (Figure 3 ).
Emergency contraceptive pill
The country with the highest use of emergency pills was Norway, with 13.5 sold packages/100 women aged 15-49 years in 2010, which decreased to 12.6 sold packages/100 women in 2013. In Sweden, 11.1 sold packages/ 100 women were reported for 2013. The lowest use was 40%   010  011  012  013  010  011  012  013  010  011  012  013  010  011  012  013  010  011  012  013   2  2  2  2  2  2  2  2  2  2  2  2  2  2  2  2  2  2 
Possible factors influencing contraceptive use
Sex education and education in contraceptive methods are provided in all five countries but are only obligary in school according to law in Denmark, Finland and Iceland (Table 3 ). In two of the Nordic countries, midwives, in addition to doctors, are certified to prescribe contraceptives and in Sweden 80% of all contraceptive prescriptions are provided by midwives. In Norway, midwives/ public health nurses were allowed to prescribe some contraceptives to teenagers during the study period (Table 3) . Some degree of financial assistance with the cost of contraception is provided in Finland, Norway and Sweden. Denmark and Iceland have no subvention at all with regard to contraception. There were also some differences between countries regarding the availability of clinical guidelines (Table 3) .
Discussion
In the Nordic countries, the use of contraception in women 15-49 years was highest in Denmark and Sweden followed by Finland. Denmark had the highest use of COC and LNG-IUS was most commonly used in Finland. In Denmark, Norway and Sweden, COC was the most used method among teenagers and young adults. Denmark tripled the use of recommended combined products during the study period, whereas Finland had a continued very low level of products recommended by the European Medicines Agency.
The main strength of this study was the use of National register data including all redeemed prescriptions of hormonal contraception from the five Nordic countries. The vast majority of women had repeat prescriptions, suggesting real use. Furthermore, there is no evidence to suggest that this potential bias differs between the countries. Female and male sterilization has decreased in recent years in Norway (15) . Data on sterilizsations were not available in all Nordic countries and were therefore not included. It was not possible in this study to obtain information about the use of less compliant methods such as condoms and natural methods.
The use of contraception was remarkably stable for each country over the four years. As in the Nordic countries, a relatively high user rate of COC has been reported in England, France, and the USA (10, (16) (17) (18) (19) . Oral contraceptives were also the primary method for 47% of women in England (4).
The use of the LNG-IUS and Cu-IUD was lower in England (4%/5%) and in the USA (6%/6%) compared with the Nordic countries (19, 20) . Finland was the first country to introduce the LNG-IUS in 1990, and this type of IUD has steadily increased its share, now accounting for more than 80% of all inserted IUDs in Finland.
Improved uptake of LARC may decrease the number of unintended pregnancies and induced abortions (8, 11) . In the USA, the proportion of LARC increased from 2.4% in 2002 to 8.5% in 2009 (21) . The European use of LARC has been estimated to be approximately 10% (22) . According to this Nordic study, the highest use of LARC was recorded in Sweden (20%) and Finland (18%), where the highest and lowest pregnancy termination rates have also been reported by the National Institute for Health and Welfare 2013.
A contributing explanation for the differences in pregnancy termination rates between the countries could be differences in user-dependent methods or less compliant methods such as condoms and natural methods, not assessed in this study. The greater use of progestin-only pills in Sweden compared with the other countries could have been influenced by media, which in Sweden frequently has reported on the potential risk of venous thrombosis with combined products, influencing women as well as the prescribing midwives to limit the use of these products (23) . It has been suggested that progestinonly pills may imply poorer bleeding control and lower continuation rates as compared with combined products, which may increase unplanned pregnancies (23) . In the Nordic countries, the majority of contraceptives are prescribed by general practitioners and gynecologists, except in Sweden, where midwives are responsible for the majority of prescriptions and often have little or no support for their decisions from doctors.
In Finland, the first LARC is provided free of charge in a few communities. In Sweden, LNG-IUS and implants are subsidized up to the age of 25 years, and Cu-IUD is (with a few exceptions) free of charge.
The 3rd National Survey of Sexual Attitudes and Lifestyles (Natsal-3) performed in the UK suggests the reported lower proportion of unplanned pregnancies may have been due to improved contraceptive services, subsidization of contraception, and that abortion has become more readily available (24) . The effect of free contraception has been seen in other studies (25, 26) . Surprisingly, Denmark, with no financial subvention of contraception at all, had the highest use of contraception among the Nordic countries. Similarly, no change was observed in the frequency of pregnancy termination in Scotland after making emergency contraception free of charge in 2008 (27) .
Easier access to emergency contraception is expected to decrease the risk of unintended pregnancies but according to a Norwegian study in 2007, when emergency contraception sales were increased in Norway no change in the rates of pregnancy termination was observed (28) . The use of emergency contraception may also reflect non-use of reliable contraceptive methods or non-compliance with oral contraceptives. In all the Nordic countries, the use of emergency contraception was largely unchanged through the study period. The highest use was reported from Norway, which in turn had the lowest overall use of regular contraception.
One of the aims of this study was to assess prescribing patterns according to the recommendations from the European Medicines Agency. Since 2009, several studies have demonstrated a risk of venous thrombosis which is about twice as high in users of low-dose COC containing desogestrel, gestodene or drospirenone as in users of low-dose COC containing levonorgestrel (29, 30) . Based on the increasing scientific evidence regarding a differential risk of thromboembolism with combined products with different progestins, updated recommendations for starters of combined products were published by the Medical Products Agency in Sweden, Norway and Denmark, followed by letters sent out by the health authorities to all doctors and midwives recommending the low-risk products as first choice. In contrast, Finland and Iceland still have no national guidelines on contraceptive use. In 2012, a Nordic survey recommended low-dose combined products containing levonorgestrel or norgestimate as first choice (12) . The European Medicines Agency came out with updated recommendations in 2013 (13) . These recommendations have been challenged by some experts. These different messages from experts have probably had an influence on the interpretation of the new scientific evidence and thereby on the clinical practice in the different countries. This study describes and compares the pattern of contraceptive use in the Nordic countries from 2010 to 2013, and reveals differences in contraceptive practice between these countries. Contraceptive use was relatively stable during the study period, but there was an increase in the use of LARC, especially in Sweden. The use of combined hormonal contraceptive products was more common in Denmark, whereas Finland had a greater use of LNG-IUS and Sweden a higher use of progestin-only pills and Cu-IUD. There were differences in adherence to European Medicines Agency recommendations regarding the use of combined products between the countries. Further studies regarding factors influencing prescribers and women's choice are necessary to improve contraceptive use and to prevent unplanned pregnancies.
